Leuvas Therapeutics, inc Epilepsy

LEUVAS THERAPEUTICS, Inc., a recently established biopharmaceutical company based in the California Bay Area and in Verona, Italy,  is  developing therapeutics that block leukocyte-vascular interactions (LVI) addressing clear unmet medical needs in large markets with potential for both first-in-class and best-in-class therapeutics addressing:

  • Refractory epilepsy
  • Epileptogenesis (following seizure, TBI, stroke)
  • Alzheimer’s disease


We are leveraging our recent discoveries  that dysfunctional endothelium, inflammatory vascular changes, and leukocyte-vascular interactions (LVI) underlie disease pathogenesis in epilepsy, Alzheimer’s Disease and other common neurodegenerative diseases.


Contact us:  info@leuvas.com

​Key Discoveries and Publications:


Neutrophils play a role in neurodegenerative disease; short-term blockade of leukocyte-vascular interactions at early and mid-stage of disease prevents cognitive decline in multiple models of Alzheimer's disease


PTPRG plays a previously unappreciated role in integrin activation and influences leukocyte migration; activation of PTPRG is a druggable target to modulate tyrosine phosphorylation.


TIM-1 is a major P-selectin ligand controlling T cell adhesion in inflamed vessels; TIM-1-mediated adhesion controls autoimmune and inflammatory disease development

  • Angiari S and Constantin G. Regulation of T cell trafficking by the T cell immunoglobulin and mucin domain 1 glycoprotein. Trends Mol Med. 2014 Dec;20(12):675-84.
  • Angiari S,  et al. TIM-1 glycoprotein binds the adhesion receptor P-selectin and mediates T cell trafficking during inflammation and autoimmunity. Immunity. 2014 Apr 17;40(4):542-53.


Therapeutic blockade of leukocyte-vascular interactions blocks seizures and prevents epileptogenesis

  • Fabene et al, (2008)A role for leukocyte-endothelial adhesion mechnisms in epilepsy.  Nat Med. 2008 Dec;14(12):1377-83.
  • Sotgiu et al (2010) Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case Report. BMC Neurol 23;10:834